In May, the company announced the failure of the monoclonal antibody birtamimab to improve mortality in a phase 3 trial of ...

Prothena will cut 63% of its workforce and evaluate a “range of business options.” Elsewhere, Zealand revealed data for a ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Prothena Corp shares climbed 5% in after-hours trading on Friday after the company said it expects to reduce its 2025 net ...

Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy. Roche, a partner of Prothena ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

DUBLIN--(BUSINESS WIRE)-- Prothena Corporation plc (NASDAQ:PRTA) today announced that the Company has initiated an approximate 63% reduction in its workforce to substantially reduce its operating ...

Citizens JMP lowered the firm’s price target on Prothena Corporation plc (NASDAQ:PRTA) to $29 from $78 but kept an Outperform rating on the shares. The notable price target decrease came after ...

Prothena has buried birtamimab for the second time. A phase 3 trial of the anti-amyloid antibody in the rare disease AL amyloidosis missed its primary endpoint, prompting the biotech to end ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Prothena said it would reduce its workforce after a recent trial failed to meet its primary and secondary endpoints. The Irish biotechnology company is planning a "substantial" job cut as it aims ...